Today, my guest is Dr. Clare Wareing, Founder and CEO of <a href='https://www.cumulusoncology.com/'>Cumulus Oncology</a>, who joins us from Edinburgh. With over 25 years of expertise in oncology drug development, Clare has built a remarkable career translating scientific breakthroughs into life-changing therapies. <a href='https://www.linkedin.com/company/cumulus-oncology/'>Cumulus Oncology</a> is curating a risk-adjusted portfolio of preclinical assets focused on high unmet needs in oncology. Their platform-agnostic, approach prioritizes patient subgroups and precision medicine to boost success rates and drive value creation.In this conversation, we explore Clare&apos;s journey to and through biotech, Cumulus and the current state of oncology in biotech, the vibrant Scottish biotech ecosystem, and her vision for the future for 2026 and beyond.01:17: Meet Clare Wareing03:57: Inspiration for founding Cumulus Oncology.05:38: Cumulus&apos;s unique drug development model.09:53: Overview of Cumulus&apos;s asset portfolio.13:05: Importance of the patient subgroup strategy.17:41: Trends in oncology drug discovery.21:09: Drivers of oncology deal-making activity.24:22: Challenges in accessing venture capital.30:06: Future milestones for Cumulus Oncology.Interested in being a sponsor of an episode of our podcast? <a href='https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&amp;utm_medium=podcast_description&amp;utm_source=podcast'>Discover how you can get involved here!</a> Stay updated by <a href='https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&amp;utm_medium=podcast_description&amp;utm_source=podcast'>subscribing to our newsletter</a>To dive deeper into the topic: <ul><li><a href='https://podcast.labiotech.eu/1995493/episodes/18242944-curing-cancer-daiichi-sankyo-s-ambitious-adc-approach'>Curing cancer: Daiichi Sankyo&apos;s ambitious ADC approach</a></li><li><a href='https://podcast.labiotech.eu/1995493/episodes/18148855-cracking-cancer-s-code-transforming-research-with-novel-cancer-models'>Cracking Cancer’s Code: Transforming Research with Novel Cancer Models</a></li><li><a href='https://www.labiotech.eu/trends-news/ztbb16-discovery-childhood-leukemia/'>New cancer cell discovery sheds light on childhood blood cancer</a></li></ul>

<description>&lt;p&gt;Today, my guest is Dr. Clare Wareing, Founder and CEO of &lt;a href='https://www.cumulusoncology.com/'&gt;Cumulus Oncology&lt;/a&gt;, who joins us from Edinburgh. &lt;/p&gt;&lt;p&gt;With over 25 years of expertise in oncology drug development, Clare has built a remarkable career translating scientific breakthroughs into life-changing therapies. &lt;a href='https://www.linkedin.com/company/cumulus-oncology/'&gt;Cumulus Oncology&lt;/a&gt; is curating a risk-adjusted portfolio of preclinical assets focused on high unmet needs in oncology. Their platform-agnostic, approach prioritizes patient subgroups and precision medicine to boost success rates and drive value creation.&lt;/p&gt;&lt;p&gt;In this conversation, we explore Clare&amp;apos;s journey to and through biotech, Cumulus and the current state of oncology in biotech, the vibrant Scottish biotech ecosystem, and her vision for the future for 2026 and beyond.&lt;/p&gt;&lt;p&gt;01:17: Meet Clare Wareing&lt;/p&gt;&lt;p&gt;03:57: Inspiration for founding Cumulus Oncology.&lt;/p&gt;&lt;p&gt;05:38: Cumulus&amp;apos;s unique drug development model.&lt;/p&gt;&lt;p&gt;09:53: Overview of Cumulus&amp;apos;s asset portfolio.&lt;/p&gt;&lt;p&gt;13:05: Importance of the patient subgroup strategy.&lt;/p&gt;&lt;p&gt;17:41: Trends in oncology drug discovery.&lt;/p&gt;&lt;p&gt;21:09: Drivers of oncology deal-making activity.&lt;/p&gt;&lt;p&gt;24:22: Challenges in accessing venture capital.&lt;/p&gt;&lt;p&gt;30:06: Future milestones for Cumulus Oncology.&lt;/p&gt;&lt;p&gt;Interested in being a sponsor of an episode of our podcast? &lt;a href='https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&amp;amp;utm_medium=podcast_description&amp;amp;utm_source=podcast'&gt;Discover how you can get involved here!&lt;/a&gt; &lt;/p&gt;&lt;p&gt;Stay updated by &lt;a href='https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&amp;amp;utm_medium=podcast_description&amp;amp;utm_source=podcast'&gt;subscribing to our newsletter&lt;/a&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;To dive deeper into the topic: &lt;/b&gt;&lt;/p&gt;&lt;ul&gt;&lt;li&gt;&lt;a href='https://podcast.labiotech.eu/1995493/episodes/18242944-curing-cancer-daiichi-sankyo-s-ambitious-adc-approach'&gt;Curing cancer: Daiichi Sankyo&amp;apos;s ambitious ADC approach&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href='https://podcast.labiotech.eu/1995493/episodes/18148855-cracking-cancer-s-code-transforming-research-with-novel-cancer-models'&gt;Cracking Cancer’s Code: Transforming Research with Novel Cancer Models&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href='https://www.labiotech.eu/trends-news/ztbb16-discovery-childhood-leukemia/'&gt;New cancer cell discovery sheds light on childhood blood cancer&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;</description>

Today, my guest is Dr. Clare Wareing, Founder and CEO of Cumulus Oncology, who joins us from Edinburgh.  With over 25 years of expertise in oncology drug development, Clare has built a remarkable career translating scientific breakthroughs into life-changing therapies. Cumulus Oncology is curating a risk-adjusted portfolio of preclinical assets focused on high unmet needs in oncology. Their platform-agnostic, approach prioritizes patient subgroups and precision medicine to boost success ...

Building a smart oncology pipeline with Cumulus Oncology

Today, we&apos;re thrilled to have <a href='https://stifelinstitutional.com/meet/tim-opler/'>Tim Opler</a>, a leading voice in biotech investment banking. Tim&apos;s career spans academia, Credit Suisse, and co-founding Torreya Partners, which Stifel acquired in 2023. As Managing Director in Stifel&apos;s Global Healthcare Group, he&apos;s advised on over 150 deals totaling more than $100 billion, shaping major M&amp;A, licensing, and financings in life sciences.Tim is renowned for his insightful Biopharma Market Updates, and in this episode, we&apos;ll dive into his December 2025 edition, where he outlines five transformative trends set to drive biopharma for the next decade: M&amp;A booms, giant markets like obesity and aging drugs, China&apos;s rising innovation, AI&apos;s reshape of healthcare, and incredible scientific advances.01:22 - Meet Tim Opler03:12 - Stifel and the Biopharma Market Updates05:50 - Trend 1: M&amp;A Booms10:06 - Trend 2: Giant Markets17:05 - Trend 3: China&apos;s Innovation22:29 - Trend 4: AI Reshaping Healthcare28:42 - Trend 5: Incredible Science34:18 - Looking forwardInterested in being a sponsor of an episode of our podcast? <a href='https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&amp;utm_medium=podcast_description&amp;utm_source=podcast'>Discover how you can get involved here!</a> Stay updated by <a href='https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&amp;utm_medium=podcast_description&amp;utm_source=podcast'>subscribing to our newsletter</a>To dive deeper into the topic: <ul><li><a href='https://www.labiotech.eu/best-biotech/china-healthcare-private-biotech-company/'>10 biotech companies in China you should know about</a></li><li><a href='https://www.labiotech.eu/in-depth/ai-physics/'>When AI isn’t enough: How physics is shaping the next wave of drug discovery </a></li><li><a href='https://www.labiotech.eu/more-news/jpm-2026/'>JPM 2026: what’s the outlook like this year? </a></li></ul>

<description>&lt;p&gt;Today, we&amp;apos;re thrilled to have &lt;a href='https://stifelinstitutional.com/meet/tim-opler/'&gt;Tim Opler&lt;/a&gt;, a leading voice in biotech investment banking. Tim&amp;apos;s career spans academia, Credit Suisse, and co-founding Torreya Partners, which Stifel acquired in 2023. As Managing Director in Stifel&amp;apos;s Global Healthcare Group, he&amp;apos;s advised on over 150 deals totaling more than $100 billion, shaping major M&amp;amp;A, licensing, and financings in life sciences.&lt;/p&gt;&lt;p&gt;Tim is renowned for his insightful Biopharma Market Updates, and in this episode, we&amp;apos;ll dive into his December 2025 edition, where he outlines five transformative trends set to drive biopharma for the next decade: M&amp;amp;A booms, giant markets like obesity and aging drugs, China&amp;apos;s rising innovation, AI&amp;apos;s reshape of healthcare, and incredible scientific advances.&lt;/p&gt;&lt;p&gt;01:22 - Meet Tim Opler&lt;/p&gt;&lt;p&gt;03:12 - Stifel and the Biopharma Market Updates&lt;/p&gt;&lt;p&gt;05:50 - Trend 1: M&amp;amp;A Booms&lt;/p&gt;&lt;p&gt;10:06 - Trend 2: Giant Markets&lt;/p&gt;&lt;p&gt;17:05 - Trend 3: China&amp;apos;s Innovation&lt;/p&gt;&lt;p&gt;22:29 - Trend 4: AI Reshaping Healthcare&lt;/p&gt;&lt;p&gt;28:42 - Trend 5: Incredible Science&lt;/p&gt;&lt;p&gt;34:18 - Looking forward&lt;/p&gt;&lt;p&gt;Interested in being a sponsor of an episode of our podcast? &lt;a href='https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&amp;amp;utm_medium=podcast_description&amp;amp;utm_source=podcast'&gt;Discover how you can get involved here!&lt;/a&gt; &lt;/p&gt;&lt;p&gt;Stay updated by &lt;a href='https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&amp;amp;utm_medium=podcast_description&amp;amp;utm_source=podcast'&gt;subscribing to our newsletter&lt;/a&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;To dive deeper into the topic: &lt;/b&gt;&lt;/p&gt;&lt;ul&gt;&lt;li&gt;&lt;a href='https://www.labiotech.eu/best-biotech/china-healthcare-private-biotech-company/'&gt;10 biotech companies in China you should know about&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href='https://www.labiotech.eu/in-depth/ai-physics/'&gt;When AI isn’t enough: How physics is shaping the next wave of drug discovery &lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href='https://www.labiotech.eu/more-news/jpm-2026/'&gt;JPM 2026: what’s the outlook like this year? &lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;</description>

Today, we're thrilled to have Tim Opler, a leading voice in biotech investment banking. Tim's career spans academia, Credit Suisse, and co-founding Torreya Partners, which Stifel acquired in 2023. As Managing Director in Stifel's Global Healthcare Group, he's advised on over 150 deals totaling more than $100 billion, shaping major M&amp;A, licensing, and financings in life sciences. Tim is renowned for his insightful Biopharma Market Updates, and in this episode, we'll dive into his December ...

Top 5 trends that will drive biopharma in the next decade with Tim Opler

Today I’m joined by not one, not two, but three guests with their takes on the biotech year ahead. In December we tasked Labiotech journalists Jules Adam, Roohi Peter, and Willow Shah-Neville with the task of identifying the five biotech players that they thought would be <a href='https://www.labiotech.eu/best-biotech/biotech-companies-to-watch-2026/'>the ones to watch in 2026</a>. Now you can read that article at Labiotech-dot-EU, and we’ve linked it in the show notes here in your podcast player, too, but on today’s episode I’m joined by Jules, Roohi, and Willow who explain a little more about the companies that caught their eye and what might be expected of those companies in the year ahead.15 companies, three journalists, all in one special podcast as we uncover the companies to watch in 2026.1:18     Meet Jules Adam2:30     Abivax4:04     AAVantgarde Bio6:10     Isotope Technologies Munich (ITM)8:16     MaaT Pharma9:55     Novo Nordisk13:15    Meet Willow Shah-Neville14:29    Kardigan18:23    Braveheart Bio21:16    Beam Therapeutics24:34    MindMed27:39    Kailera Therapeutics32:36    Meet Roohi Peter33:30    Aspen Neuroscience34:45    Reunion Neuroscience36:14    MapLight Therapeutiucs37:41    Hope Medicine38:59    RegenxbioInterested in being a sponsor of an episode of our podcast? <a href='https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&amp;utm_medium=podcast_description&amp;utm_source=podcast'>Discover how you can get involved here!</a> Stay updated by <a href='https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&amp;utm_medium=podcast_description&amp;utm_source=podcast'>subscribing to our newsletter</a>To dive deeper into the topic: <ul><li><a href='https://www.labiotech.eu/best-biotech/biotech-companies-to-watch-2026/'>Keep an eye on these 15 biotech companies in 2026 </a></li><li><a href='https://www.labiotech.eu/in-depth/biotech-2025-restrospective/'>Biotech in 2025: A retrospective </a></li><li><a href='https://www.labiotech.eu/best-biotech/immunology-inflammation-deals/'>Eight of the biggest immunology and inflammation (I&amp;I) deals in 2025</a></li></ul>

<description>&lt;p&gt;Today I’m joined by not one, not two, but three guests with their takes on the biotech year ahead. In December we tasked Labiotech journalists Jules Adam, Roohi Peter, and Willow Shah-Neville with the task of identifying the five biotech players that they thought would be &lt;a href='https://www.labiotech.eu/best-biotech/biotech-companies-to-watch-2026/'&gt;&lt;b&gt;the ones to watch in 2026&lt;/b&gt;&lt;/a&gt;. Now you can read that article at Labiotech-dot-EU, and we’ve linked it in the show notes here in your podcast player, too, but on today’s episode I’m joined by Jules, Roohi, and Willow who explain a little more about the companies that caught their eye and what might be expected of those companies in the year ahead.&lt;/p&gt;&lt;p&gt;15 companies, three journalists, all in one special podcast as we uncover the companies to watch in 2026.&lt;/p&gt;&lt;p&gt;&lt;b&gt;1:18     Meet Jules Adam&lt;/b&gt;&lt;/p&gt;&lt;p&gt;2:30     Abivax&lt;/p&gt;&lt;p&gt;4:04     AAVantgarde Bio&lt;/p&gt;&lt;p&gt;6:10     Isotope Technologies Munich (ITM)&lt;/p&gt;&lt;p&gt;8:16     MaaT Pharma&lt;/p&gt;&lt;p&gt;9:55     Novo Nordisk&lt;/p&gt;&lt;p&gt;&lt;b&gt;13:15    Meet Willow Shah-Neville&lt;/b&gt;&lt;/p&gt;&lt;p&gt;14:29    Kardigan&lt;/p&gt;&lt;p&gt;18:23    Braveheart Bio&lt;/p&gt;&lt;p&gt;21:16    Beam Therapeutics&lt;/p&gt;&lt;p&gt;24:34    MindMed&lt;/p&gt;&lt;p&gt;27:39    Kailera Therapeutics&lt;/p&gt;&lt;p&gt;&lt;b&gt;32:36    Meet Roohi Peter&lt;/b&gt;&lt;/p&gt;&lt;p&gt;33:30    Aspen Neuroscience&lt;/p&gt;&lt;p&gt;34:45    Reunion Neuroscience&lt;/p&gt;&lt;p&gt;36:14    MapLight Therapeutiucs&lt;/p&gt;&lt;p&gt;37:41    Hope Medicine&lt;/p&gt;&lt;p&gt;38:59    Regenxbio&lt;/p&gt;&lt;p&gt;Interested in being a sponsor of an episode of our podcast? &lt;a href='https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&amp;amp;utm_medium=podcast_description&amp;amp;utm_source=podcast'&gt;Discover how you can get involved here!&lt;/a&gt; &lt;/p&gt;&lt;p&gt;Stay updated by &lt;a href='https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&amp;amp;utm_medium=podcast_description&amp;amp;utm_source=podcast'&gt;subscribing to our newsletter&lt;/a&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;To dive deeper into the topic: &lt;/b&gt;&lt;/p&gt;&lt;ul&gt;&lt;li&gt;&lt;a href='https://www.labiotech.eu/best-biotech/biotech-companies-to-watch-2026/'&gt;Keep an eye on these 15 biotech companies in 2026 &lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href='https://www.labiotech.eu/in-depth/biotech-2025-restrospective/'&gt;Biotech in 2025: A retrospective &lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href='https://www.labiotech.eu/best-biotech/immunology-inflammation-deals/'&gt;Eight of the biggest immunology and inflammation (I&amp;amp;I) deals in 2025&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;</description>

Today I’m joined by not one, not two, but three guests with their takes on the biotech year ahead. In December we tasked Labiotech journalists Jules Adam, Roohi Peter, and Willow Shah-Neville with the task of identifying the five biotech players that they thought would be the ones to watch in 2026. Now you can read that article at Labiotech-dot-EU, and we’ve linked it in the show notes here in your podcast player, too, but on today’s episode I’m joined by Jules, Roohi, and Willow who explain ...

Labiotech's 15 biopharma companies to watch in 2026

Welcome to our first episode for 2026.Today, we&apos;re joined by Hakan Goker, Managing Director at <a href='https://www.m-ventures.com'>M Ventures</a>, the strategic corporate venture capital arm of Merck KGaA. With over two decades in biotech investing, Hakan has driven transformative deals in oncology, autoimmune diseases, and beyond, including standout 2025 investments like FoRx Therapeutics and portfolio milestones such as Artios&apos; FDA Fast Track designation. As we kick off 2026 at Beyond Biotech, Hakan shares insights on corporate VC advantages, emerging therapeutic priorities, and the industry&apos;s evolving landscape amid rising M&amp;A and AI innovation. 1:10                 Meet Hakan Goka4:37                 About M Ventures and pharma CVC8:14                 Sourcing innovative biotechs12:52                How M Ventures works with Merck KGaA16:54              M Ventures in 202524:46                Areas to watch in the new year29:19                Looking forward to 202632:20                The next big thing in biotech?33:08                Advice for biotechs pitching CVCInterested in being a sponsor of an episode of our podcast? <a href='https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&amp;utm_medium=podcast_description&amp;utm_source=podcast'>Discover how you can get involved here!</a> Stay updated by <a href='https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&amp;utm_medium=podcast_description&amp;utm_source=podcast'>subscribing to our newsletter</a>To dive deeper into the topic: <ul><li><a href='https://www.labiotech.eu/expert-advice/biotech-startup-funding/'>The ABC of biotech startup funding</a></li><li><a href='https://www.labiotech.eu/best-biotech/genome-sequencing-startups-to-look-out-for/'>Seven genome sequencing companies to look out for</a></li><li><a href='https://www.labiotech.eu/biotech-funding-2025-tracker/'>Labiotech&apos;s 2025 biotech funding tracker</a></li></ul>

<description>&lt;p&gt;Welcome to our first episode for 2026.&lt;/p&gt;&lt;p&gt;Today, we&amp;apos;re joined by Hakan Goker, Managing Director at &lt;a href='https://www.m-ventures.com'&gt;M Ventures&lt;/a&gt;, the strategic corporate venture capital arm of Merck KGaA. With over two decades in biotech investing, Hakan has driven transformative deals in oncology, autoimmune diseases, and beyond, including standout 2025 investments like FoRx Therapeutics and portfolio milestones such as Artios&amp;apos; FDA Fast Track designation. &lt;/p&gt;&lt;p&gt;As we kick off 2026 at Beyond Biotech, Hakan shares insights on corporate VC advantages, emerging therapeutic priorities, and the industry&amp;apos;s evolving landscape amid rising M&amp;amp;A and AI innovation. &lt;/p&gt;&lt;p&gt;1:10                 Meet Hakan Goka&lt;/p&gt;&lt;p&gt;4:37                 About M Ventures and pharma CVC&lt;/p&gt;&lt;p&gt;8:14                 Sourcing innovative biotechs&lt;/p&gt;&lt;p&gt;12:52                How M Ventures works with Merck KGaA&lt;/p&gt;&lt;p&gt;16:54              M Ventures in 2025&lt;/p&gt;&lt;p&gt;24:46                Areas to watch in the new year&lt;/p&gt;&lt;p&gt;29:19                Looking forward to 2026&lt;/p&gt;&lt;p&gt;32:20                The next big thing in biotech?&lt;/p&gt;&lt;p&gt;33:08                Advice for biotechs pitching CVC&lt;/p&gt;&lt;p&gt;Interested in being a sponsor of an episode of our podcast? &lt;a href='https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&amp;amp;utm_medium=podcast_description&amp;amp;utm_source=podcast'&gt;Discover how you can get involved here!&lt;/a&gt; &lt;/p&gt;&lt;p&gt;Stay updated by &lt;a href='https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&amp;amp;utm_medium=podcast_description&amp;amp;utm_source=podcast'&gt;subscribing to our newsletter&lt;/a&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;To dive deeper into the topic: &lt;/b&gt;&lt;/p&gt;&lt;ul&gt;&lt;li&gt;&lt;a href='https://www.labiotech.eu/expert-advice/biotech-startup-funding/'&gt;The ABC of biotech startup funding&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href='https://www.labiotech.eu/best-biotech/genome-sequencing-startups-to-look-out-for/'&gt;Seven genome sequencing companies to look out for&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href='https://www.labiotech.eu/biotech-funding-2025-tracker/'&gt;Labiotech&amp;apos;s 2025 biotech funding tracker&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;</description>

Welcome to our first episode for 2026. Today, we're joined by Hakan Goker, Managing Director at M Ventures, the strategic corporate venture capital arm of Merck KGaA. With over two decades in biotech investing, Hakan has driven transformative deals in oncology, autoimmune diseases, and beyond, including standout 2025 investments like FoRx Therapeutics and portfolio milestones such as Artios' FDA Fast Track designation.  As we kick off 2026 at Beyond Biotech, Hakan shares insights on corp...

M Ventures: pharma CVC and biotech innovation in 2026

Welcome to our final episode for 2025. We’re taking a little break for the holidays but we’ll be back again on Friday 9th of January to kick off our year with the Managing Director of Merck KGaA’s M Ventures, Hakan Goker.Today, though, I’m joined by Ester in t’Groen of <a href='https://www.jnj.com/innovativemedicine/emea/'>Johnson &amp; Johnson</a>.Fresh off the American Society of Hematology (ASH) Annual Meeting in Orlando, where J&amp;J presented over 60 abstracts, Ester shares insights into the company&apos;s portfolio and the advances that the company has made over recent years in the hematology space.She walks us through the real-world evidence for some pretty significant results from the thousands of patients in their clinical trials, and explain what&apos;s next for J&amp;J in hematology in 2026—including some exciting readouts.01:14 - Meet Ester in t&apos;Groen    02:37 - Winning the Kilmer Medal06:32 - J&amp;J&apos;s key focus areas07:32 - The hematology portfolio19:07 - All about ASH 202523:49 - The MajesTEC-3 data27:43 - The value of real-world datasets32:06 - Looking forward into 2026Interested in being a sponsor of an episode of our podcast? <a href='https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&amp;utm_medium=podcast_description&amp;utm_source=podcast'>Discover how you can get involved here!</a> Stay updated by <a href='https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&amp;utm_medium=podcast_description&amp;utm_source=podcast'>subscribing to our newsletter</a>To dive deeper into the topic: <ul><li><a href='https://www.labiotech.eu/in-depth/blood-cancer-awarness-month-promising-pipeline-clinical-trials/'>Blood Cancer Awareness Month: What biotech holds in store </a></li><li><a href='https://www.labiotech.eu/best-biotech/oncology-deals-2025/'>10 oncology deals in 2025 spotlight where industry leaders are betting big</a></li><li><a href='https://www.labiotech.eu/in-depth/t-cell-engagers-review/'>T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments</a></li></ul>

<description>&lt;p&gt;Welcome to our final episode for 2025. We’re taking a little break for the holidays but we’ll be back again on Friday 9th of January to kick off our year with the Managing Director of Merck KGaA’s M Ventures, Hakan Goker.&lt;/p&gt;&lt;p&gt;Today, though, I’m joined by Ester in t’Groen of &lt;a href='https://www.jnj.com/innovativemedicine/emea/'&gt;Johnson &amp;amp; Johnson&lt;/a&gt;.&lt;/p&gt;&lt;p&gt;Fresh off the American Society of Hematology (ASH) Annual Meeting in Orlando, where J&amp;amp;J presented over 60 abstracts, Ester shares insights into the company&amp;apos;s portfolio and the advances that the company has made over recent years in the hematology space.&lt;/p&gt;&lt;p&gt;She walks us through the real-world evidence for some pretty significant results from the thousands of patients in their clinical trials, and explain what&amp;apos;s next for J&amp;amp;J in hematology in 2026—including some exciting readouts.&lt;/p&gt;&lt;p&gt;01:14 - Meet Ester in t&amp;apos;Groen    &lt;/p&gt;&lt;p&gt;02:37 - Winning the Kilmer Medal&lt;/p&gt;&lt;p&gt;06:32 - J&amp;amp;J&amp;apos;s key focus areas&lt;/p&gt;&lt;p&gt;07:32 - The hematology portfolio&lt;/p&gt;&lt;p&gt;19:07 - All about ASH 2025&lt;/p&gt;&lt;p&gt;23:49 - The MajesTEC-3 data&lt;/p&gt;&lt;p&gt;27:43 - The value of real-world datasets&lt;/p&gt;&lt;p&gt;32:06 - Looking forward into 2026&lt;/p&gt;&lt;p&gt;Interested in being a sponsor of an episode of our podcast? &lt;a href='https://www.labiotech.eu/advertise/?utm_campaign=lead_generation&amp;amp;utm_medium=podcast_description&amp;amp;utm_source=podcast'&gt;Discover how you can get involved here!&lt;/a&gt; &lt;/p&gt;&lt;p&gt;Stay updated by &lt;a href='https://www.labiotech.eu/newsletter/?utm_campaign=newsletter_promotion&amp;amp;utm_medium=podcast_description&amp;amp;utm_source=podcast'&gt;subscribing to our newsletter&lt;/a&gt;&lt;/p&gt;&lt;p&gt;&lt;b&gt;To dive deeper into the topic: &lt;/b&gt;&lt;/p&gt;&lt;ul&gt;&lt;li&gt;&lt;a href='https://www.labiotech.eu/in-depth/blood-cancer-awarness-month-promising-pipeline-clinical-trials/'&gt;Blood Cancer Awareness Month: What biotech holds in store &lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href='https://www.labiotech.eu/best-biotech/oncology-deals-2025/'&gt;10 oncology deals in 2025 spotlight where industry leaders are betting big&lt;/a&gt;&lt;/li&gt;&lt;li&gt;&lt;a href='https://www.labiotech.eu/in-depth/t-cell-engagers-review/'&gt;T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments&lt;/a&gt;&lt;/li&gt;&lt;/ul&gt;</description>

Welcome to our final episode for 2025. We’re taking a little break for the holidays but we’ll be back again on Friday 9th of January to kick off our year with the Managing Director of Merck KGaA’s M Ventures, Hakan Goker. Today, though, I’m joined by Ester in t’Groen of Johnson &amp; Johnson. Fresh off the American Society of Hematology (ASH) Annual Meeting in Orlando, where J&amp;J presented over 60 abstracts, Ester shares insights into the company's portfolio and the advances that the compa...

Johnson & Johnson’s hematology portfolio: breakthroughs to watch

Welcome to the official Labiotech.eu podcast - Beyond Biotech! Each week, we talk about what's happening in the world of biotech, with news and interviews with experts from companies around the world. Join us as we cover the latest news, breakthroughs and innovations shaping the life sciences industry.A new podcast episode is available every Friday. The host is Dylan Kissane.

Beyond Biotech - the podcast from Labiotech

Details

Recent Episodes